Japan Tobacco Inc. (JT) (TSE: 2914) today announced that F. Hoffmann-La Roche Ltd. (Roche) issued a press release on the termination of the development of JTT-705 (dalcetrapib). JT has concluded a licensing agreement for JTT-705 (dalcetrapib) with Roche in October 2004, granting Roche the rights to develop and commercialize the drug worldwide except for Japan, and currently Roche has been conducting several phase 3 clinical trials.
JTT-705 (dalcetrapib) was discovered by JT with the objective of increasing plasma HDL (High Density Lipoprotein), by modulation of CETP (Cholesteryl Ester Transfer Protein) which transfers cholesterol from HDL to LDL (Low Density Lipoprotein). This is expected to have only a small impact on JT's consolidated account in this financial year.
About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D
Buy cheap cigarettes from Europe.
Комментариев нет:
Отправить комментарий